Androgens in prostate cancer: A tale that never ends
Androgens play an essential role in prostate cancer. Clinical treatments that target steroidogenesis and the androgen receptor (AR) successfully postpone disease progression. Abiraterone and enzalutamide, the next-generation androgen receptor pathway inhibitors (ARPI), emphasize the function of the...
Gespeichert in:
| Veröffentlicht in: | Cancer letters 2021-09, Vol.516, p.1-12 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 12 |
|---|---|
| container_issue | |
| container_start_page | 1 |
| container_title | Cancer letters |
| container_volume | 516 |
| creator | Hou, Zemin Huang, Shengsong Li, Zhenfei |
| description | Androgens play an essential role in prostate cancer. Clinical treatments that target steroidogenesis and the androgen receptor (AR) successfully postpone disease progression. Abiraterone and enzalutamide, the next-generation androgen receptor pathway inhibitors (ARPI), emphasize the function of the androgen-AR axis even in castration-resistant prostate cancer (CRPC). However, with the increased incidence in neuroendocrine prostate cancer (NEPC) showing resistance to ARPI, the importance of androgen-AR axis in further disease management remains elusive. Herein we review the steroidogenic pathways associated with different disease stages and discuss the potential targets for disease management after manifesting resistance to abiraterone and enzalutamide.
•The steroidogenic pathways in prostate cancer cells are accommodated to different clinical treatments.•Steroidogenic enzymes are promising targets for further disease treatment.•Supraphysiological testosterone is another innovative strategy to treat prostate cancer. |
| doi_str_mv | 10.1016/j.canlet.2021.04.010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2535104927</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0304383521001701</els_id><sourcerecordid>2547537850</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-1f772989b841b22ecb364508f9f712766fd4dadebc3d63ab1764f2313867d8943</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMouq7-A5GCFy-tk482qQdhWfyCBS96Dmky1S7dVpOs4L83UvXgwdNcnnnnnYeQEwoFBVpdrAtrhh5jwYDRAkQBFHbIjCrJclkr2CUz4CByrnh5QA5DWANAKWS5Tw64gJJxJmdELAbnx2ccQtYN2asfQzQRsxRt0V9miyyaHrP4YmI24Dv6DAcXjshea_qAx99zTp5urh-Xd_nq4fZ-uVjlltcQc9pKyWpVN0rQhjG0Da9ECaqtW0mZrKrWCWccNpa7ipuGykq0jFOuKulULficnE-5qdfbFkPUmy5Y7Hsz4LgNmpW8pCBqJhN69gddj1s_pHaJSk9zqUpIlJgomx4NHlv96ruN8R-agv6yqtd6sqq_rGoQOllNa6ff4dtmg-536UdjAq4mAJON9w69DrbDpNB1Hm3Ubuz-v_AJLTaHDA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2547537850</pqid></control><display><type>article</type><title>Androgens in prostate cancer: A tale that never ends</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Hou, Zemin ; Huang, Shengsong ; Li, Zhenfei</creator><creatorcontrib>Hou, Zemin ; Huang, Shengsong ; Li, Zhenfei</creatorcontrib><description>Androgens play an essential role in prostate cancer. Clinical treatments that target steroidogenesis and the androgen receptor (AR) successfully postpone disease progression. Abiraterone and enzalutamide, the next-generation androgen receptor pathway inhibitors (ARPI), emphasize the function of the androgen-AR axis even in castration-resistant prostate cancer (CRPC). However, with the increased incidence in neuroendocrine prostate cancer (NEPC) showing resistance to ARPI, the importance of androgen-AR axis in further disease management remains elusive. Herein we review the steroidogenic pathways associated with different disease stages and discuss the potential targets for disease management after manifesting resistance to abiraterone and enzalutamide.
•The steroidogenic pathways in prostate cancer cells are accommodated to different clinical treatments.•Steroidogenic enzymes are promising targets for further disease treatment.•Supraphysiological testosterone is another innovative strategy to treat prostate cancer.</description><identifier>ISSN: 0304-3835</identifier><identifier>EISSN: 1872-7980</identifier><identifier>DOI: 10.1016/j.canlet.2021.04.010</identifier><identifier>PMID: 34052327</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Abiraterone resistance ; Adrenal glands ; Androgen receptor ; Androgen Receptor Antagonists - pharmacology ; Androgen receptors ; Androgens ; Androgens - metabolism ; Animals ; Biopsy ; Bipolar androgen therapy ; Castration ; Cholesterol ; Dehydrogenases ; Disease management ; Disease resistance ; Drug Resistance, Neoplasm - drug effects ; Enzalutamide resistance ; Enzymes ; Humans ; Male ; Medical research ; Metabolites ; Mortality ; Prostate cancer ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - metabolism ; Receptors, Androgen - metabolism ; Steroidogenesis ; Testes ; Testosterone</subject><ispartof>Cancer letters, 2021-09, Vol.516, p.1-12</ispartof><rights>2021 Elsevier B.V.</rights><rights>Copyright © 2021 Elsevier B.V. All rights reserved.</rights><rights>2021. Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-1f772989b841b22ecb364508f9f712766fd4dadebc3d63ab1764f2313867d8943</citedby><cites>FETCH-LOGICAL-c390t-1f772989b841b22ecb364508f9f712766fd4dadebc3d63ab1764f2313867d8943</cites><orcidid>0000-0002-6700-3092 ; 0000-0001-6520-431X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.canlet.2021.04.010$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34052327$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hou, Zemin</creatorcontrib><creatorcontrib>Huang, Shengsong</creatorcontrib><creatorcontrib>Li, Zhenfei</creatorcontrib><title>Androgens in prostate cancer: A tale that never ends</title><title>Cancer letters</title><addtitle>Cancer Lett</addtitle><description>Androgens play an essential role in prostate cancer. Clinical treatments that target steroidogenesis and the androgen receptor (AR) successfully postpone disease progression. Abiraterone and enzalutamide, the next-generation androgen receptor pathway inhibitors (ARPI), emphasize the function of the androgen-AR axis even in castration-resistant prostate cancer (CRPC). However, with the increased incidence in neuroendocrine prostate cancer (NEPC) showing resistance to ARPI, the importance of androgen-AR axis in further disease management remains elusive. Herein we review the steroidogenic pathways associated with different disease stages and discuss the potential targets for disease management after manifesting resistance to abiraterone and enzalutamide.
•The steroidogenic pathways in prostate cancer cells are accommodated to different clinical treatments.•Steroidogenic enzymes are promising targets for further disease treatment.•Supraphysiological testosterone is another innovative strategy to treat prostate cancer.</description><subject>Abiraterone resistance</subject><subject>Adrenal glands</subject><subject>Androgen receptor</subject><subject>Androgen Receptor Antagonists - pharmacology</subject><subject>Androgen receptors</subject><subject>Androgens</subject><subject>Androgens - metabolism</subject><subject>Animals</subject><subject>Biopsy</subject><subject>Bipolar androgen therapy</subject><subject>Castration</subject><subject>Cholesterol</subject><subject>Dehydrogenases</subject><subject>Disease management</subject><subject>Disease resistance</subject><subject>Drug Resistance, Neoplasm - drug effects</subject><subject>Enzalutamide resistance</subject><subject>Enzymes</subject><subject>Humans</subject><subject>Male</subject><subject>Medical research</subject><subject>Metabolites</subject><subject>Mortality</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Prostatic Neoplasms - metabolism</subject><subject>Receptors, Androgen - metabolism</subject><subject>Steroidogenesis</subject><subject>Testes</subject><subject>Testosterone</subject><issn>0304-3835</issn><issn>1872-7980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LxDAQhoMouq7-A5GCFy-tk482qQdhWfyCBS96Dmky1S7dVpOs4L83UvXgwdNcnnnnnYeQEwoFBVpdrAtrhh5jwYDRAkQBFHbIjCrJclkr2CUz4CByrnh5QA5DWANAKWS5Tw64gJJxJmdELAbnx2ccQtYN2asfQzQRsxRt0V9miyyaHrP4YmI24Dv6DAcXjshea_qAx99zTp5urh-Xd_nq4fZ-uVjlltcQc9pKyWpVN0rQhjG0Da9ECaqtW0mZrKrWCWccNpa7ipuGykq0jFOuKulULficnE-5qdfbFkPUmy5Y7Hsz4LgNmpW8pCBqJhN69gddj1s_pHaJSk9zqUpIlJgomx4NHlv96ruN8R-agv6yqtd6sqq_rGoQOllNa6ff4dtmg-536UdjAq4mAJON9w69DrbDpNB1Hm3Ubuz-v_AJLTaHDA</recordid><startdate>20210928</startdate><enddate>20210928</enddate><creator>Hou, Zemin</creator><creator>Huang, Shengsong</creator><creator>Li, Zhenfei</creator><general>Elsevier B.V</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6700-3092</orcidid><orcidid>https://orcid.org/0000-0001-6520-431X</orcidid></search><sort><creationdate>20210928</creationdate><title>Androgens in prostate cancer: A tale that never ends</title><author>Hou, Zemin ; Huang, Shengsong ; Li, Zhenfei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-1f772989b841b22ecb364508f9f712766fd4dadebc3d63ab1764f2313867d8943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Abiraterone resistance</topic><topic>Adrenal glands</topic><topic>Androgen receptor</topic><topic>Androgen Receptor Antagonists - pharmacology</topic><topic>Androgen receptors</topic><topic>Androgens</topic><topic>Androgens - metabolism</topic><topic>Animals</topic><topic>Biopsy</topic><topic>Bipolar androgen therapy</topic><topic>Castration</topic><topic>Cholesterol</topic><topic>Dehydrogenases</topic><topic>Disease management</topic><topic>Disease resistance</topic><topic>Drug Resistance, Neoplasm - drug effects</topic><topic>Enzalutamide resistance</topic><topic>Enzymes</topic><topic>Humans</topic><topic>Male</topic><topic>Medical research</topic><topic>Metabolites</topic><topic>Mortality</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Prostatic Neoplasms - metabolism</topic><topic>Receptors, Androgen - metabolism</topic><topic>Steroidogenesis</topic><topic>Testes</topic><topic>Testosterone</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hou, Zemin</creatorcontrib><creatorcontrib>Huang, Shengsong</creatorcontrib><creatorcontrib>Li, Zhenfei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hou, Zemin</au><au>Huang, Shengsong</au><au>Li, Zhenfei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Androgens in prostate cancer: A tale that never ends</atitle><jtitle>Cancer letters</jtitle><addtitle>Cancer Lett</addtitle><date>2021-09-28</date><risdate>2021</risdate><volume>516</volume><spage>1</spage><epage>12</epage><pages>1-12</pages><issn>0304-3835</issn><eissn>1872-7980</eissn><abstract>Androgens play an essential role in prostate cancer. Clinical treatments that target steroidogenesis and the androgen receptor (AR) successfully postpone disease progression. Abiraterone and enzalutamide, the next-generation androgen receptor pathway inhibitors (ARPI), emphasize the function of the androgen-AR axis even in castration-resistant prostate cancer (CRPC). However, with the increased incidence in neuroendocrine prostate cancer (NEPC) showing resistance to ARPI, the importance of androgen-AR axis in further disease management remains elusive. Herein we review the steroidogenic pathways associated with different disease stages and discuss the potential targets for disease management after manifesting resistance to abiraterone and enzalutamide.
•The steroidogenic pathways in prostate cancer cells are accommodated to different clinical treatments.•Steroidogenic enzymes are promising targets for further disease treatment.•Supraphysiological testosterone is another innovative strategy to treat prostate cancer.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>34052327</pmid><doi>10.1016/j.canlet.2021.04.010</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-6700-3092</orcidid><orcidid>https://orcid.org/0000-0001-6520-431X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0304-3835 |
| ispartof | Cancer letters, 2021-09, Vol.516, p.1-12 |
| issn | 0304-3835 1872-7980 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2535104927 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Abiraterone resistance Adrenal glands Androgen receptor Androgen Receptor Antagonists - pharmacology Androgen receptors Androgens Androgens - metabolism Animals Biopsy Bipolar androgen therapy Castration Cholesterol Dehydrogenases Disease management Disease resistance Drug Resistance, Neoplasm - drug effects Enzalutamide resistance Enzymes Humans Male Medical research Metabolites Mortality Prostate cancer Prostatic Neoplasms - drug therapy Prostatic Neoplasms - metabolism Receptors, Androgen - metabolism Steroidogenesis Testes Testosterone |
| title | Androgens in prostate cancer: A tale that never ends |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T19%3A40%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Androgens%20in%20prostate%20cancer:%20A%20tale%20that%20never%20ends&rft.jtitle=Cancer%20letters&rft.au=Hou,%20Zemin&rft.date=2021-09-28&rft.volume=516&rft.spage=1&rft.epage=12&rft.pages=1-12&rft.issn=0304-3835&rft.eissn=1872-7980&rft_id=info:doi/10.1016/j.canlet.2021.04.010&rft_dat=%3Cproquest_cross%3E2547537850%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2547537850&rft_id=info:pmid/34052327&rft_els_id=S0304383521001701&rfr_iscdi=true |